

Elazar Rabbani et al.

Serial No. 09/439,594

Filed: November 12, 1999

Page 3 [Communication (Directed To August 15, 2003 Notice Of Non-Compliant  
Amendment (Voluntary Revised Practice) – September 16, 2003]

### REMARKS

This Communication is in response to the August 15, 2003 Notice of Non-Compliant Amendment (Voluntary Revised Practice). In the August 15, 2003 Notice, the Team Leader indicated that Applicants' August 8, 2003 Amendment "does not fully comply with the minimal requirements of the voluntary practice. . ."

The Team Leader further indicated:

2. The listing of claims does not include the text of all claims currently under examination. Claims 147-165, 167-182 and 184-200 texts are missing.


In response, Applicants are re-submitting herewith as Exhibit B their Amendment Under 37 C.F.R. ¶1.115 (In Response To The July 30, 2003 Office Action). Applicants' re-submitted Amendment (Exhibit B) has been re-dated and revised to include the missing text of pending claims. The Amendment (Exhibit B) also includes their re-dated Terminal Disclaimer To Obviate A Provisional Double Patenting Rejection Over A Pending Second Application (attached as Exhibit 1 to the Amendment).

Entry of Applicants' Amendment (Exhibit B) is respectfully requested.

It is believed that Applicants' newly submitted Amendment (Exhibit B) fully complies with the current rules on amendment practice.

Favorable action on this application is also respectfully requested.

Respectfully submitted,

  
Ronald C. Fedus

Registration No. 32,567  
Attorney for Applicants

ENZO LIFE SCIENCES, INC.  
(formerly named Enzo Diagnostics, Inc.)  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
Telephone: (212) 583-0100  
Fax: (212) 583-0150

Enz-58(D1)